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Recent emergence of a third generation of mechanistic 
target  of  rapamycin (mTOR) inhibi tors ,  termed 
RapaLink-1, have generated hope in treatment of 
glioblastoma, the most aggressive primary brain tumor in 
adults. Produced by coupling first and second generation 
mTOR inhibitors (1), RapaLink-1 displays superior efficacy 
in inhibition of the mTOR complex I (mTORC1) pathway. 
This led to the inhibition of proliferation with relatively 
longer durability in glioblastoma cells and xenograft models. 
Importantly, RapaLink-1 crosses the blood-brain barrier 
and effectively targets mutant mTOR glioblastoma cells. 
RapaLink-1 is a bivalent inhibitor generated by combining 
the analogue inhibitor of mTOR, rapamycin, with the ATP-
competitive inhibitor of mTOR, MLN0128. The resulting 
compound is more potent than first- and second-generation 
mTOR inhibitors. Investigation by Fan et al. [2017] (1) 
examined the effect of RapaLink-1 and RapaLink-2 on 
glioblastoma cell growth and proliferation by targeting the 
mTORC1.
mTOR is a member of the phosphoinositide 3-kinase-
related kinase (PI3K)  family with homologs in all 
eukaryotes (2,3). The N-terminus of mTOR contains 
several huntingtin elongation factor 3 protein phosphatase 
2A TOR1 (HEAT) repeats to facilitate the majority 
of interactions with other proteins. The FKB-FRAP 
domain that directly binds to rapamycin is located at the 
C-terminus of the mTOR protein. The C-terminus also 
contains a kinase domain that places it in the PI3K family. 
The canonical PI3K/Akt/mTOR signaling axis regulates 
various physiological functions including cellular growth, 
proliferation, differentiation, and metabolism (2,4,5). 
Hyperactivation of mTOR signaling in cancers occurs 
via multiple mechanisms (6) and results in an increase 
in cell growth, causing some cell types to enter the cell 
cycle. Aberrant mTOR pathway activity is prevalent in 
glioblastoma, leading to abnormalities in cell proliferation 
and motility, thereby resulting in uncontrolled growth 
and dissemination (7,8). Mutations of PTEN are found 
in approximately 70–90% of glioblastoma that leads to 
deregulation of the PI3K/Akt/mTOR signaling axis. In 
addition to frequent deletions and mutations of the tumor 
suppressor PTEN, about 86% of the glioblastoma samples 
display at least one genetic event leading to activation of the 
RTK/PI3K pathway (9). Constitutive activation of mTOR 
via single point mutations has been shown in many cancers, 
including glioblastoma (10). Hyper-activation of mTOR 
signaling makes it an attractive target for therapeutic 
intervention. In fact, first-generation mTOR inhibitors, 
rapamycin, and its analogue, rapalogs, exclusively bind to 
the component of mTORC1 and inhibit mTOR activity 
with limited success in clinical settings. Among these 
agents, first-generation mTOR inhibitors, rapamycin, and 
its analogue, rapalogs, inhibit mTOR by forming a complex 
with the immunophilin FKBP12. FKBP12 then exclusively 
binds directly to the component of mTORC1 (4). Second 
generation ATP-competitive inhibitor of mTOR shows 
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potent and selective inhibition of mTORC1 and mTORC2. 
It also shows anti-proliferative activity, however, it is limited 
in suppressing mTORC1. Resistant glioblastoma cells as 
well as therapy related formation of mutant mTOR were 
the major obstacles of mTOR inhibitors. 
Creation of  RapaLink,  the third generation of 
mTOR complex inhibitors, was achieved by linking first 
generation analogue binding inhibitor, rapamycin, to the 
second generation inhibitor, MLN0128, hence termed, 
RapaLink (Figure 1). Two forms of RapaLink were created: 
RapaLink-1 and Rapalink-2, which differ in size of linker 
length. RapaLink-1was superior in inhibiting mTOR 
complex as it potently reduced levels of both p-4EBP1, an 
important component of mTORC1, and cell proliferation 
as compared with RapaLink-2. RapaLink-1 was shown 
to be more potent in inhibiting glioblastoma cell growth 
inhibition as well as halting cells in G0/G1 of the cell 
cycle as compared to rapamycin or MLN0128 alone. As 
expected, rapamycin suppressed the mTORC1 target, 
p-RPS6S235/236, and MLN0128 inhibited both the mTORC1 
targets p-RPS6S235/236 and p-4EBP1T37/46,  as well as 
mTORC2 targets p-AKTS473 in a dose-dependent manner. 
In this investigation, Fan et al. [2017] (1) demonstrated 
that RapaLink-1 selectively inhibited p-RPS6S235/236 and 
p-4EBP1T37/46 at a low dose of 1.56 nM. Suppression of 
mTORC2 was achieved at higher doses only in two human 
glioblastoma cell lines, LN229 and U87MG, and in short-
term primary cultures from patient-derived xenografts. It is 
important to note that glioblastoma may develop new driver 
mutations in response to therapies, including activating 
mutations in mTOR itself. Crucially, RapaLink-1 effectively 
reduced cell proliferation of glioblastoma cells expressing 
either wild-type or activating mutation of mTOR, namely 
mTORR2505P and mTORS2115Y. Rapamycin treatment also 
caused a significant suppression in cell growth irrespective 
of mTOR status, albeit to a lesser extent as compared to 
RapaLink-1. On the other hand, MLN0128 treatment was 
less effective in cells expressing mutant mTOR. Fan et al. 
[2017] (1) further demonstrated that RapaLink-1 blocked 
activation of p-4EBP1T37/46 regardless of mutational status of 
mTOR. In contrast, levels of p-4EBP1T37/46 remained higher 
in mTOR mutant glioblastoma cells treated with rapamycin 
or MLN08. These results strengthened the effectiveness of 
RapaLink-1 as compared to first- and second-generation 
mTOR inhibitors.
Rapamycin and its chemically related compounds have 
recently been used in clinical trials for the treatment 
of cancer due to their inhibitory effects on the mTOR 
pathway (12). Clinical trials using rapamycin and its 
analogs (CCI-779/temsirolimus, RAD001/everolimus, and 
AP23573) have shown promising yet challenging results in 
the management of various tumors including glioblastoma. 
In fact, a trial by Cloughesy et al. [2008] (13) showed that 
rapamycin successfully reduced tumor growth in half of 
Figure 1 Schematic representation of mTOR structure showing FRB and kinase domains (11), where novel bivalent mTOR inhibitor 
RapaLink binds, which is created by linking analogue inhibitor rapamycin and ATP-competitive inhibitor MLN0128 to the regions of FRB 
and kinase of mTOR, respectively (1). Also shown in this figure are two multiprotein complexes of mTOR, mTORC1 and mTORC2 (see 
text for details). mTOR, mechanistic target of rapamycin; mTORC, mTOR complex 1.
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the patients with PTEN-deficient, recurrent glioblastoma. 
However, there were challenges in targeting the mTOR 
pathway as a significant number of patients showed an 
increased level of phosphorylated AKT and PRAS40. It 
was concluded that this activation could be due to loss 
of negative feedback, resulting in decreased time for 
progression free-survival in these patients, causing poor 
clinical outcomes (13). This particular trial stands out as it 
demonstrates the molecular mechanisms of glioblastoma 
developing resistance to rapamycin and its analogs. 
Specifically, this trial establishes the limited therapeutic 
effectiveness of mTOR inhibition with rapamycin and its 
analogs due to loss of negative feedback. Therefore, despite 
significant advancement in targeted therapy, glioblastoma 
remains incurable possibly in part due to activation of 
mitogenic pathways such as RAS/ERK1/2 (7,8). Preclinical 
and clinical studies of ATP-competitive mTOR inhibitors 
that target both mTORC1 and mTORC2 demonstrated 
greater effectiveness than rapalogs in treatment of cancer. 
However, it is important to consider that the acute 
mTORC1 inhibition can activate the negative feedback 
loop leading to triggering of PI3K/PDK1/Akt (Thr308) 
and IRS1 via mitogenic pathways, leading to relentless cell 
survival and proliferation (7,8). 
In vivo studies performed in mTOR xenograft models 
using BALB/Cnu/nu mice, administered daily I.P. injections 
of vehicle, MLN0128, rapamycin, or RapaLink-1 every 
5th day, showed that RapaLink-1 inhibited components 
of mTORC1, p-RPS6S235/236 and p-4EBP1T37/46 in a dose-
dependent manner in the brain. Conversely, it failed to 
inhibit the mTORC2 substrate p-AKTS473 in vivo. An 
important observation of this study was that RapaLink 
crosses through the blood-brain barrier (1). Furthermore, 
experiments revealing tumor burden, mTOR signaling, and 
survival analysis revealed that RapaLink-1 caused regression 
and subsequent stabilization of tumor size. In contrast 
vehicle, rapamycin, or MLN0128-treated mice displayed 
a steady growth in their tumor. Furthermore, RapaLink-1 
blocked the expression of p-4EBP1T37/46 while MLN0128 
or rapamycin had modest effects in reducing the levels of 
p-4EBP1T37/46. Suppression of p-RPS6S235/236 was achieved 
in all treatment groups individually, however inhibition 
of mTORC2 substrate p-AKTS473 was achieved only after 
treatment with MLN0128.
Further in this study, xenograft/mice-treated with 
inhibitors were followed for survival/analyses, which 
showed that RapaLink-1 treated animals had much 
improved survival as compared to vehicle, MLN012, 
or rapamycin-treated animals. In addition, proliferative 
index was robustly suppressed by RapaLink-1 treatment 
whereas it was only modestly suppressed by rapamycin 
or MLN0128 treatments. Authors further demonstrated 
that patient-derived glioblastoma cells in xenograft models 
displayed a marked reduction in tumor growth following IP 
administration of RapaLink-1 when analyzed by luciferase 
signal as compared with vehicle, rapamycin, or MLN0128 
treatments (1). As with earlier treatments, RapaLink-1 
efficiently blocked the expression of p-4EBP1T37/46 in 
tumors, while both MLN0128 and rapamycin only 
modestly reduced p-4EBP1T37/46. Levels of p-RPS6S235/236 
remained indistinctly suppressed by all treatments and 
MLN0128 exclusively inhibited p-AKTS473. Structurally, 
binding of rapamycin to FKBP12 and FRAP is subjected 
to two different hydrophobic binding pockets which helps 
occupancy of rapamycin in cells leading to a sustained 
suppression of mTORC1 substrate, p-RPS6S235/236 (14). 
Fan et al. [2017] (1) showed that RapaLink-1 compared 
with both rapamycin and MLN0128 was most effective in 
suppressing human glioma cell growth for a long period of 
time and phosphorylation of RPS6 and 4EBP1 was down-
regulated over a period of 24 h.
First and second generation inhibitors of mTOR 
displayed incomplete effects in glioblastoma tumors in both 
preclinical and clinical studies. Rapamycin and its analogues 
allosteric inhibitors inhibit mTORC1 by targeting S6K 
without inhibiting 4EBP1 (15). On the other hand, 
MLN0128 was more effective than rapamycin in in vitro 
studies, as it was able to inhibit mTORC1 target 4EBP1, 
but displayed shorter residence time (16). An improved 
efficacy of RapaLink-1 in in vivo studies may be attributed to 
its ability to efficiently block 4EBP1 as well as its prolonged 
residence time. Furthermore, in glioblastoma, 4EBP1is 
considered as a more reliable marker for mTORC1 activity 
and therefore inhibition of 4EBP1 is crucial in suppressing 
mTOR activity (17). RapaLink-1 treated cells showed 
higher levels of FKBP12 bound compared with cells treated 
with rapamycin. The rapamycin-FKBP12 complex binds 
only to FRB, whereas the RapaLink-1-FKBP12 complex 
binds to FRB and to the mTOR kinase domain, thereby 
increasing affinity as well as stability leading to higher 
efficacy. Despite its size, RapaLink-1 was able to cross the 
blood-brain barrier and induce regression of tumor burden 
in orthotopic/xenograft models for brain cancer. This class 
of agents thus holds promise for future therapy of patients 
with glioblastoma.
While RapaLink-1 promoted regression in glioblastoma 
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models, this initial regression was followed by regrowth 
of the tumor. Such recurrence is consistent with data 
suggesting that mTOR inhibitors as monotherapies are 
not sufficient to achieve anti-tumor responses in most 
cancers (6). Studies to establish the basis for recurrence, 
such as induction of autophagy, negative feedback loops, 
rewiring, or acquisition of resistance by emergence of novel 
mutations will determine the means that promote apoptosis 
and overcome resistance to position RapaLink-1 for clinical 
development in treatment of glioblastoma.
The mTORC1 complex is composed of proteins such as 
regulatory associated protein of mTOR (RAPTOR), which 
is sensitive to rapamycin treatment. It has been shown that 
mTORC1 function is tightly regulated by PI3K/AKT. In 
contrast to mTORC1, the mTORC2 complex is sensitive 
to growth factors but not nutrients, and is associated with 
the rapamycin-insensitive companion of mTOR (RICTOR) 
along with other proteins (11). The major distinguishing 
characteristic of the mTORC1 and mTORC2 is their 
differential sensitivity to rapamycin (5). mTORC1 regulates 
protein synthesis through phosphorylating its downstream 
substrates, 4EBP1 (also called EIF4EBP1) and p70 
S6K1/2 (11). The mTOR-dependent phosphorylation 
of p70 S6K1/2 promotes translation initiation as well as 
elongation and regulates cellular growth (11). mTORC2 
modulates growth factor signaling by phosphorylating the 
C-terminal hydrophobic motif of some AGC kinases, such 
as AKT and SGK. Pharmacological inhibition of these 
complexes has been difficult to achieve. A phase I trial 
of rapamycin in PTEN-deficient glioblastoma patients 
showed some promising results with inherent difficulties 
of targeting mTOR pathways. A significant number of 
patients showed increased activated levels of pAKTSer473 
following rapamycin treatment, which was correlated with 
shorter time to progression. The observed AKT activation 
was likely due to an alteration of signaling feedback loops, 
highlighting the complexity of prolonged rapamycin 
treatment. 
Rapamycin (sirolimus) and its analogs, RAD001 
(everolimus) and CCI-779 (temsirolimus), suppress 
mTOR activity through an allosteric mechanism that acts 
at a distance from the ATP binding catalytic site. Major 
disadvantages of rapamycin and other related compounds 
are that it suppresses TORC1 mediated S6K activation, 
thereby blocking a negative feedback loop. This led to the 
activation of PI3K/AKT and Ras/MEK/ERK signaling 
pathways, promoting cell survival and growth. Rapamycin 
remains an incomplete inhibitor of mTORC1 (18). In recent 
years, novel small ATP binding site molecules have been 
identified that directly inhibit mTOR, unlike rapamycin, 
which is an allosteric inhibitor of mTOR. In addition, 
novel ATP binding compounds with pyrazolopyrimidines 
are shown to inhibit members of the PI3K family, 
including mTOR. One such compound, PP242, is an ATP-
competitive inhibitor of mTOR, which shows potent and 
selective inhibition of mTORC1 and mTORC2 (19). These 
molecules are often phrased “TORKinibs” for their ability 
to inhibit TOR kinase. First-generation TORi compounds 
such as PP242 inhibits mTORC1/C2 in AKT/mTOR 
signaling. Novel MLN0128, a second-generation of TORi 
compound (20), appears to be more potent.
Limitations of rapalogs-based clinical strategies have 
pushed toward the development of a second generation of 
mTOR inhibitors known as ATP-competitive mTOR kinase 
inhibitors (TORKIs), which target the kinase domain of 
mTOR and inhibit its catalytic activity. From a mechanistic 
point of view, the advantage of these drugs relies on the 
ability of inhibiting the kinase activity of both the TORC1 
and TORC2 complexes while also blocking the feedback 
activation of PI3K/Akt signaling (18,21,22). Combinatory 
strategies may provide a way to overcome such resistance 
and therefore improve efficacy of mTOR targeting agents 
in the clinical context (23). In addition, mTOR has also 
been involved in regulation of stem cells (3).
The development of a third generation of mTOR 
inhibitors, such as RapaLink-1, holds the potential to 
overcome the resistance to the rapaloge or TORKi, perhaps 
due to its ability to bind to two drug-binding pockets of 
mTOR (Figure 1). As demonstrated in breast cancer cells, 
RapaLink-1 has the ability to target MCF-7 cells that 
carried three somatic mutations within mTOR, FRB-
FKBP1, or Kinase domain conferring resistance (24). It is 
important to realize that the hyperactive M2327I mutation 
as seen here, similar to other mTOR kinase domain 
mutations, are seen in patients with no prior treatments (25), 
which may influence the sensitivity to ATP-competitive 
mTOR inhibitors. While FRB-domain mutations can 
cause resistance to therapy by disrupting the interaction 
of FKBP12-rapamycin complex to mTOR, influencing 
the binding of the inhibitor, the Kinase domain mutations 
cause hyperactivation of the kinase activity. Marked by 
such challenges, a drug-modeling technique has created a 
novel bivalent mTOR inhibitor such as Rapalink. Rapalink 
consists of a rapamycin-FRB-binding compound linked 
to a TORKi, which can target both FRB-domain as well 
as Kinase domain of mTOR. RapaLink potently inhibits 
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the mTORC1 pathway by inhibiting the phosphorylation 
of 4EBP1 and growth inhibition both in vitro and in vivo, 
at levels comparable to rapamycin or a combination of 
rapamycin with MLN0128. Importantly, RapaLink-1also 
targets cells expressing specific mTOR mutations. 
In summary, inhibition of the mTOR pathway following 
bivalent kinase inhibitor has proven to be therapeutic 
for glioblastoma and future clinical studies are expected 
to reveal the significance of such unique approaches. It 
is not unreasonable to envision that such therapeutic 
options may be effective in successfully treating patients 
with hyperactive mTOR kinase domain mutations and/or 
those who have developed resistance to rapalogs or ATP-
competitive inhibitors. Future clinical trials may suggest 
whether RapaLink-1 results in therapy related resistance 
or activates alternate pathways due to the loss of negative 
feedback. Nevertheless, it is worth noting that bivalent 
kinase inhibitors such as Rapalink-1 are unique in design as 
described by Fan et al. (1) to provide more stable and potent 
suppressive effects on mTOR pathways in glioblastoma. 
Therefore, studies such as those presented here using 
novel bivalent inhibitors may serve as the initial foundation 
for developing innovative strategies in treatment of fatal 
cancers such as glioblastoma.
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